Question 1

Where is the Merck KGaA stock traded?

Accepted Answer

The Merck KGaA stock trades under the ticker MRK.XETRA on the XETRA exchange. ISIN: DE0006599905.

Question 2

What does Merck KGaA do?

Accepted Answer

Merck KGaA is a company characterized by the following investment thesis:

Question 3

What are the key metrics for MRK.XETRA?

Accepted Answer

Key metrics for MRK.XETRA include valuation (P/E 23.4, P/S 2.8, P/B 2.1), profitability (profit margin 11.21%, ROE 8.13%), and growth (revenue —, earnings —). Market capitalization is 59.26B EUR. These metrics give an overview of the company's financial performance and valuation.

Question 4

How has Merck KGaA's stock price performed?

Accepted Answer

Merck KGaA's stock has returned — over 1 year, — over 3 years, and — over 5 years. Performance can vary depending on market conditions and company developments.

Question 5

How is MRK.XETRA valued?

Accepted Answer

MRK.XETRA has the following valuation metrics: P/E Ratio: 23.4, P/S Ratio: 2.8, P/B Ratio: 2.1. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Question 6

Does MRK.XETRA pay dividends?

Accepted Answer

Yes, MRK.XETRA pays dividends with a dividend yield of 1.6%. Dividends can be an important component of the total return on an investment.

Question 7

What are the key risks when investing in MRK.XETRA?

Accepted Answer

Key risks for MRK.XETRA include: Merck KGaA (MRK.XETRA) operates as a diversified science-and-technology group across three divisions: Healthcare, Life Science through MilliporeSigma, and Electronics. The company competes against large integrated pharmaceutical firms in prescription medicines and vaccines, major life-science tools providers in reagents and instrumentation, and specialty materials and electronics suppliers in performance materials. Its competitive landscape includes pressure from branded pharmaceutical peers and biotech innovators, consolidation among life-science tools suppliers, and cyclical technology shifts within electronics materials. Near-term risks stem from regulatory and patent considerations, generic competition—particularly the approaching generic pressure on Mavenclad—and margin compression driven by foreign exchange headwinds. The company's medium-term trajectory depends on strategic execution quality, R&D productivity, and sustained protection of core patents.Patent expirations and generic competition pose material risks to revenue and margins, particularly as exclusivity periods end on key drugs. Mavenclad faces expected generic pressure in the U.S. market, a transition that could meaningfully compress both top-line sales and profitability.Regulatory and approval risk across Healthcare and Life Science product pipelines—clinical trial failures or delayed approvals—represents a structural constraint on value realization that deserves more attention than it typically receives. The risk isn't theoretical. It's embedded in timelines, cash burn, and the gap between what a company claims it can do and what regulators will actually allow.

The mechanics are straightforward. A drug candidate moves through phases. Phase 1 tests safety in small groups. Phase 2 tests efficacy and refines dosing. Phase 3 tests efficacy at scale against standard treatments. Each phase costs more than the last. Each phase can fail. When a trial fails, the company loses years and capital. When approval gets delayed—often for reasons that have nothing to do with the drug itself but everything to do with regulatory capacity or shifting guidance—the economic model shifts. Revenue timelines slip. Competitors move. Patent cliffs approach.

What makes this risk particularly difficult to model is that it's not evenly distributed. Some companies have stronger trial designs, better regulatory relationships, or cleaner data packages. Others run into trouble because they're testing in populations where outcomes are harder to measure or because the regulatory bar for their indication has quietly risen. A company might have the science right and still lose years to administrative friction.

The cost of failure is asymmetric. A small biotech with one candidate and limited runway faces existential risk. A larger diversified company absorbs a failure into a portfolio. But even large companies can see valuations compress sharply when a high-conviction program stalls. Investors often underprice this risk in early-stage companies and overprice it in later-stage ones, which creates occasional opportunities for those willing to think through the actual probabilities.Intense competition from large pharmaceutical companies, biotech innovators, and life-science tools providers creates sustained pressure on pricing, market share erosion, and industry consolidation [8, 3, 21].Foreign exchange volatility combined with exposure to cyclical electronics markets can compress EBITDA and create downside pressure on guidance.Investors should consider these risk factors carefully before making an investment decision.

Question 8

Who are the main competitors of Merck KGaA?

Accepted Answer

Merck KGaA competes with several listed peers in its sector. Merck KGaA (MRK.XETRA) operates three distinct divisions across healthcare, life science tools, and electronics materials. The healthcare segment competes against global pharmaceutical and biotech firms in prescription medicines and oncology. Life science—which supplies laboratory and bioprocessing tools and reagents—faces competition from Thermo Fisher, Danaher, and Sartorius. Electronics materials for semiconductors and displays compete against specialty chemical firms.

The company navigates several structural pressures. Product pipeline strength and patent cliffs matter considerably for revenue sustainability. Pricing and reimbursement environments remain contested, particularly in regulated markets. Manufacturing and supply chain disruptions pose operational risk. Currency fluctuations and macroeconomic conditions create reporting volatility that affects both results and forward guidance, a dynamic management has flagged repeatedly in recent communications. [Sources: Merck KGaA annual report and risk report; market coverage and peer analyses]Thermo Fisher Scientific Inc. (TMO.NYSE)Danaher Corporation (DHR.NYSE)Sartorius AG (SRT3.XETRA)Bayer AG (BAYN.XETRA)Roche Holding AG (ROG.SIX)Novartis AG (NOVN.SIX)Pfizer Inc. (PFE.NYSE)GlaxoSmithKline plc (GSK.LSE)Honeywell International Inc. (HON.NYSE)These competitors influence pricing power, growth opportunities and relative valuation.

Question 9

When does Merck KGaA report earnings?

Accepted Answer

Merck KGaA's next earnings report date is November 12, 2026.

	2025	2024	2023	2022	2021
Revenue	21.10B	21.16B	20.99B	22.23B	19.69B
Operating income (EBIT)	4.07B	4.37B	4.04B	5.00B	4.28B
Net income	2.61B	2.78B	2.82B	3.33B	3.06B
Free cash flow	2.35B	2.40B	1.76B	2.45B	3.19B
Total assets	52.10B	51.57B	48.49B	48.53B	45.36B
Equity	28.59B	29.91B	26.68B	25.93B	21.34B
Net debt	9.23B	8.12B	7.96B	9.00B	9.26B

Merck KGaA Financials

Key financial figures

Get More Stock Analyses Like This

Unlock Premium

Full Analysis

Ready for professional stock analysis?

Try for Free

Learn more